Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Social Media Monitoring: The Next Frontier In Corp. Integrity Agreements?

This article was originally published in The Pink Sheet Daily

Executive Summary

Expert questions whether companies could be required to monitor social media posts and search engine results as part of a future corporate integrity agreement.

You may also be interested in...



FDA’s Twitter Formula Allows Tweets About Products Without Excessive Risks

FDA’s draft guidance on presenting product information on social media platforms with character space limitations includes an equation for sending a tweet.

DDMAC Dislike: FDA Cracks Down On Facebook Widget Used On Tasigna Website

Agency says Novartis' "Facebook Share" items, which users can post on their Facebook walls, must include risk along with efficacy information.

Internet Searching May Get ‘Riskier’ For Patients After FDA Citations

“Sponsored searches” need to contain risk information, agency tells 14 firms in letters covering 48 products.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

PS076498

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel